Related references
Note: Only part of the references are listed.PEGylated TNF-Related Apoptosis-Inducing Ligand (TRAIL) Analogues: Pharmacokinetics and Antitumor Effects
Tae Hyung Kim et al.
BIOCONJUGATE CHEMISTRY (2011)
Combined modality therapy with TRAIL or agonistic death receptor antibodies
Hope M. Amm et al.
CANCER BIOLOGY & THERAPY (2011)
Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis
M. Hoernle et al.
ONCOGENE (2011)
The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein
Jonas Hopp et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins
B. Schneider et al.
CELL DEATH & DISEASE (2010)
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma
Johannes Haybaeck et al.
CANCER CELL (2009)
Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways
Daniela Berg et al.
FEBS JOURNAL (2009)
Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway
Kuen-Feng Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
B. ten Cate et al.
LEUKEMIA (2009)
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies
Bruno Christian Koehler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity
Anja Krippner-Heidenreich et al.
JOURNAL OF IMMUNOLOGY (2008)
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non-small cell lung cancers
Jacqueline F. Doody et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
Faiy H. Psahoulia et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Lipid rafts and nonrafts mediate tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic and nonapoptotic signals in non-small cell lung carcinoma cells
Jin H. Song et al.
CANCER RESEARCH (2007)
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Ronald Koschny et al.
CLINICAL CANCER RESEARCH (2007)
The promise of TRAIL - potential and risks of a novel anticancer therapy
Ronald Koschny et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
Almer M. van der Sloot et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs
TM Ganten et al.
CLINICAL CANCER RESEARCH (2006)
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
M MacFarlane et al.
CANCER RESEARCH (2005)
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten et al.
HEPATOLOGY (2005)
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum
N Seidel et al.
HEPATOLOGY (2005)
Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2
E Bremer et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Evaluation of nuclear factor-κB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma
CF Chan et al.
CLINICAL CANCER RESEARCH (2004)
Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours
M Ng et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)
TNF-Selectokine:: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor
T Wüest et al.
ONCOGENE (2002)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma
M Volkmann et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2001)
Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
H Wajant et al.
ONCOGENE (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
Share Paper
